{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:25:35Z","timestamp":1792513535858,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s40264-021-01125-4","type":"journal-article","created":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T11:02:50Z","timestamp":1641985370000},"page":"127-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Use of Identical INN \u201cImiglucerase\u201d for Different Drug Products: Impact Analysis of Adverse Events in a Proprietary Global Safety Database"],"prefix":"10.1007","volume":"45","author":[{"given":"So-Fai","family":"Tsang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirali","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Barakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Keutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leorah","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9873-8078","authenticated-orcid":false,"given":"Selena","family":"Freisens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"issue":"18","key":"1125_CR1","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000;160(18):2835\u201343. https:\/\/doi.org\/10.1001\/archinte.160.18.2835.","journal-title":"Arch Intern Med"},{"issue":"4","key":"1125_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","volume":"147","author":"PK Mistry","year":"2009","unstructured":"Mistry PK, Deegan P, Vellodi A, Cole JA, Yeh M, Weinreb NJ. Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. Br J Haematol. 2009;147(4):561\u201370. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07872.x.","journal-title":"Br J Haematol"},{"issue":"6","key":"1125_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/j.1399-0004.2007.00811.x","volume":"71","author":"N Weinreb","year":"2007","unstructured":"Weinreb N, Barranger J, Packman S, Prakash-Cheng A, Rosenbloom B, Sims K, et al. Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet. 2007;71(6):576\u201388. https:\/\/doi.org\/10.1111\/j.1399-0004.2007.00811.x.","journal-title":"Clin Genet"},{"issue":"2","key":"1125_CR4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/s0002-9343(02)01150-6","volume":"113","author":"NJ Weinreb","year":"2002","unstructured":"Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112\u20139. https:\/\/doi.org\/10.1016\/s0002-9343(02)01150-6.","journal-title":"Am J Med"},{"issue":"3","key":"1125_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013;36(3):543\u201353. https:\/\/doi.org\/10.1007\/s10545-012-9528-4.","journal-title":"J Inherit Metab Dis"},{"issue":"1433","key":"1125_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1098\/rstb.2003.1269","volume":"358","author":"RO Brady","year":"2003","unstructured":"Brady RO. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci. 2003;358(1433):915\u20139. https:\/\/doi.org\/10.1098\/rstb.2003.1269.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"1125_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1542\/peds.2007-2144","volume":"122","author":"H Andersson","year":"2008","unstructured":"Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics. 2008;122(6):1182\u201390. https:\/\/doi.org\/10.1542\/peds.2007-2144.","journal-title":"Pediatrics"},{"issue":"2","key":"1125_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/01.gim.0000153660.88672.3c","volume":"7","author":"HC Andersson","year":"2005","unstructured":"Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med. 2005;7(2):105\u201310. https:\/\/doi.org\/10.1097\/01.gim.0000153660.88672.3c.","journal-title":"Genet Med"},{"issue":"21","key":"1125_CR9","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/nejm199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease. N Engl J Med. 1991;324(21):1464\u201370. https:\/\/doi.org\/10.1056\/nejm199105233242104.","journal-title":"N Engl J Med"},{"issue":"3","key":"1125_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","volume":"71","author":"J Charrow","year":"2007","unstructured":"Charrow J, Dulisse B, Grabowski GA, Weinreb NJ. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet. 2007;71(3):205\u201311. https:\/\/doi.org\/10.1111\/j.1399-0004.2007.00769.x.","journal-title":"Clin Genet"},{"issue":"2","key":"1125_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0268-960x(98)90023-6","volume":"12","author":"GA Grabowski","year":"1998","unstructured":"Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease: the first 5 years. Blood Rev. 1998;12(2):115\u201333. https:\/\/doi.org\/10.1016\/s0268-960x(98)90023-6.","journal-title":"Blood Rev"},{"issue":"5","key":"1125_CR12","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","volume":"73","author":"KB Sims","year":"2008","unstructured":"Sims KB, Pastores GM, Weinreb NJ, Barranger J, Rosenbloom BE, Packman S, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study. Clin Genet. 2008;73(5):430\u201340. https:\/\/doi.org\/10.1111\/j.1399-0004.2008.00978.x.","journal-title":"Clin Genet"},{"key":"1125_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","volume":"10","author":"NJ Weinreb","year":"2015","unstructured":"Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, et al. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3). Orphanet J Rare Dis. 2015;10:64. https:\/\/doi.org\/10.1186\/s13023-015-0280-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1125_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1182\/blood-2003-11-3854","volume":"104","author":"RJ Wenstrup","year":"2004","unstructured":"Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, Wu W, et al. Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood. 2004;104(5):1253\u20137. https:\/\/doi.org\/10.1182\/blood-2003-11-3854.","journal-title":"Blood"},{"key":"1125_CR15","unstructured":"World Health Organization. Guidance on the use of international nonproprietary names (INNs) for pharmaceutical substances. Geneva: World Health Organization; 2017. https:\/\/www.who.int\/medicines\/services\/inn\/FINAL_WHO_PHARM_S_NOM_1570_web.pdf?ua=1. Accessed 28 Sept 2021."},{"key":"1125_CR16","unstructured":"Abcertin [package insert]. ISU Abxis. Seoul; 2014."},{"key":"1125_CR17","unstructured":"Asbroder [product information sheet]. Laboratorios PiSA, S.A. de C.V. Guadalajara, Jai; 2014."},{"key":"1125_CR18","unstructured":"Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris), Marketing Authorization, Asbroder, at 2 (Nov. 10, 2015) (identifying ISU Abxis as the manufacturer of Asbroder\u2019s active substance, and Laboratorios PiSA S.A. de C.V. as the marketing authorization holder). https:\/\/www.gob.mx\/cms\/uploads\/attachment\/file\/196773\/Huerfanos_Otorgados_2015.pdf. Accessed 28 Sept 2021."},{"key":"1125_CR19","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products. 23 October 2014. Committee for medicinal products for human use (CHMP). CHMP\/437\/04 Rev 1. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf. Accessed 28 Sept 2021."},{"key":"1125_CR20","unstructured":"US Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product guidance for industry. 2015. https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm291128.pdf. Accessed 28 Sept 2021."},{"key":"1125_CR21","unstructured":"World Health Organization. Regulatory expectations and risk assessment for biotherapeutic products. 2014. http:\/\/www.who.int\/biologicals\/WHO_Risk_Assessment_for_Biotherapeutics_1st_PC_24_Jan_2014.pdf. Accessed 28 Sept 2021."},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"71","DOI":"10.5639\/gabij.2019.0802.008","volume":"8","author":"G Casta\u00f1eda-Hernandez","year":"2019","unstructured":"Casta\u00f1eda-Hernandez G, Carbajai-Rodriguez L, Ceron-Rodriguez M, et al. Are there biosimilar orphan drugs for Gaucher disease? GaBi J. 2019;8:71\u20135. https:\/\/doi.org\/10.5639\/gabij.2019.0802.008.","journal-title":"GaBi J."},{"issue":"3","key":"1125_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ajh.25701","volume":"95","author":"G Drelichman","year":"2020","unstructured":"Drelichman G, Castaneda-Hernandez G, Cem Ar M, Dragosky M, Garcia R, Lee H, et al. The road to biosimilars in rare diseases: ongoing lessons from Gaucher disease. Am J Hematol. 2020;95(3):233\u20137. https:\/\/doi.org\/10.1002\/ajh.25701.","journal-title":"Am J Hematol"},{"key":"1125_CR24","unstructured":"GaBI Online. Generics and biosimilars initiative: biosimilar substitution in Europe. Belgium: Pro Pharma Communications International. http:\/\/www.gabionline.net\/Reports\/Biosimilar-substitution-in-Europe. Accessed 26 June 2018."},{"key":"1125_CR25","unstructured":"Cerezyme (imiglucerase) [summary of product characteristics]. Cambridge: Sanofi Genzyme; 2020."},{"key":"1125_CR26","unstructured":"Cerezyme (imiglucerase). [package insert]. Cambridge; Sanofi Genzyme; 2020."},{"issue":"2","key":"1125_CR27","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","volume":"90","author":"K Starzyk","year":"2007","unstructured":"Starzyk K, Richards S, Yee J, Smith SE, Kingma W. The long-term international safety experience of imiglucerase therapy for Gaucher disease. Mol Genet Metab. 2007;90(2):157\u201363. https:\/\/doi.org\/10.1016\/j.ymgme.2006.09.003.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1125_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","volume":"90","author":"E Ponce","year":"1997","unstructured":"Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood. 1997;90(1):43\u20138.","journal-title":"Blood"},{"issue":"6","key":"1125_CR29","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","volume":"93","author":"M Rosenberg","year":"1999","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood. 1999;93(6):2081\u20138.","journal-title":"Blood"},{"issue":"3","key":"1125_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ajh.25701","volume":"95","author":"G Drelichman","year":"2020","unstructured":"Drelichman G, Casta\u00f1eda-Hern\u00e1ndez G, Cem Ar M, Dragosky M, Garcia R, Lee H, et al. The road to biosimilars in rare diseases: ongoing lessons from Gaucher disease. Am J Hematol. 2020;95(3):233\u20137. https:\/\/doi.org\/10.1002\/ajh.25701.","journal-title":"Am J Hematol"},{"key":"1125_CR31","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module VI: management and reporting of adverse reactions to medicinal products. EMA\/873138\/2011 Rev. London: European Medicines Agency; 2011."},{"key":"1125_CR32","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP). Module I: pharmacovigilance systems and their quality systems. EMA\/541760\/2011. London: European Medicines Agency; 2011."},{"key":"1125_CR33","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH E2A: clinical safety data management: definitions and standards for expedited reporting; 1994."},{"key":"1125_CR34","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH E2C (R2): periodic benefit-risk evaluation report (PBRER). 2003."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01125-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01125-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,18]],"date-time":"2022-02-18T13:30:09Z","timestamp":1645191009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01125-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01125-4","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"assertion":[{"value":"21 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded by Sanofi Genzyme.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"At the time of submission, SP and SF were employees of Sanofi Genzyme. JK retired from Sanofi Genzyme, and KB, ST, GL, and LR are former employees of Sanofi Genzyme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Pharmacovigilance data are collected as part of a routine safety follow-up for all approved products.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The data are anonymous and cannot be associated with any patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data that support the findings of this study are available from Sanofi Genzyme, but restrictions apply to the availability of these data that are not publicly available. Data are, however, available upon reasonable request and with permission of Sanofi Genzyme.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ST, JK, LR, and SF developed the concept for the study. SP drafted the original manuscript. All authors were involved in the analysis and interpretation of the data, read the manuscript, provided critical revisions, approved the final manuscript, and have accountability for the accuracy and integrity of the content.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}